Ionis Pharmaceuticals (NASDAQ:IONS) Issues Quarterly Earnings Results

Ionis Pharmaceuticals (NASDAQ:IONS) released its quarterly earnings data on Monday. The company reported ($0.66) EPS for the quarter, beating analysts’ consensus estimates of ($1.23) by $0.57, Zacks reports. The business had revenue of $242.72 million during the quarter, compared to the consensus estimate of $178.17 million. Ionis Pharmaceuticals had a negative return on equity of 115.54% and a negative net margin of 56.98%. The firm’s revenue was up 54.8% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.80) earnings per share.

Here are the key takeaways from Ionis Pharmaceuticals’ conference call:

• Ionis lowered 2026 TRYNGOLZA sales guidance to approximately $50 million after a slower-than-expected launch ramp. Management cited the time needed to build a new treatment market, broaden repeat prescribing and secure payer coverage, while maintaining its view of multi-billion-dollar peak sales potential.
• DAWNZERA sales rose about 40% sequentially to $37 million in Q3, with growth in repeat prescribers and use among patients with varied treatment histories. Ionis maintained its 2026 sales guidance of $110 million to $120 million.
• Third-quarter revenue was $243 million, up 55% year over year excluding a prior-year one-time payment, and the company reiterated its 2026 revenue, operating-loss and cash outlook. Ionis ended the quarter with $1.9 billion in cash and investments.
• Following phase III setbacks for eplontersen in ATTR cardiomyopathy and pelacarsen in cardiovascular disease, Ionis shifted its expected timing for sustained positive cash flow from 2028 to 2029. Management also said the slower TRYNGOLZA launch contributed to the revised timing.
• Pipeline and product milestones included U.S. approval of ZANVASTRO, with the first commercial patients treated, and HIBSAGO approval in the U.S. and Japan. Ionis also reported positive phase III results for partnered sefaxersen in IgA nephropathy and ulefnersen in FUS-ALS.

Ionis Pharmaceuticals Price Performance

Shares of IONS stock opened at $29.02 on Wednesday. The stock’s 50-day moving average is $45.54 and its 200 day moving average is $65.36. The company has a debt-to-equity ratio of 3.07, a current ratio of 7.89 and a quick ratio of 7.73. Ionis Pharmaceuticals has a 1-year low of $27.75 and a 1-year high of $86.74. The company has a market cap of $4.82 billion, a P/E ratio of -8.75 and a beta of 0.43.

Insider Activity at Ionis Pharmaceuticals

In related news, EVP Shannon Devers sold 1,357 shares of Ionis Pharmaceuticals stock in a transaction that occurred on Friday, October 16th. The shares were sold at an average price of $43.54, for a total value of $59,083.78. Following the completion of the sale, the executive vice president directly owned 17,811 shares in the company, valued at $775,490.94. This trade represents a 7.08% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Corporate insiders own 1.81% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the company. Barclays reduced their price target on Ionis Pharmaceuticals from $90.00 to $85.00 and set an “overweight” rating for the company in a research report on Wednesday, September 9th. BMO Capital Markets raised shares of Ionis Pharmaceuticals from a “market perform” rating to an “outperform” rating and upped their price objective for the company from $54.00 to $66.00 in a research note on Thursday, October 22nd. Royal Bank Of Canada dropped their price objective on shares of Ionis Pharmaceuticals from $85.00 to $60.00 and set an “outperform” rating on the stock in a research note on Tuesday. Citigroup reissued a “buy” rating on shares of Ionis Pharmaceuticals in a research report on Wednesday, October 21st. Finally, Bank of America restated a “buy” rating on shares of Ionis Pharmaceuticals in a research note on Tuesday. Nineteen equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $78.00.

Key Headlines Impacting Ionis Pharmaceuticals

Here are the key news stories impacting Ionis Pharmaceuticals this week:

• Positive Sentiment: Third-quarter revenue rose 55% year over year to $242.7 million, beating estimates, and the company’s quarterly loss was narrower than analysts expected. Ionis Pharmaceuticals Delivers 55% Revenue Growth in Q3 2026
• Positive Sentiment: DAWNZERA sales increased 40% to $37 million, providing a positive commercial-growth signal. Ionis: 3 Key Takeaways for Long-Term Investors
• Neutral Sentiment: Despite reducing price targets, Oppenheimer, Morgan Stanley, HC Wainwright, and Needham retained outperform, overweight, or buy ratings. Goldman Sachs lowered its target and maintained a neutral rating. These views suggest analysts see potential recovery, while target cuts reflect increased caution. Ionis Pharmaceuticals analyst coverage
• Negative Sentiment: Ionis cut its 2026 TRYNGOLZA sales outlook to about $50 million, from its prior $100 million–$110 million forecast, citing slower uptake and competitive pressure. The reduction has weakened confidence in the launch and is the key reported driver of the selloff. Ionis Q3 Revenue Rises; Lowers TRYNGOLZA Sales Outlook
• Negative Sentiment: The company’s 2026 revenue guidance of $875 million–$900 million is below the $920.8 million analyst consensus. Multiple law firms also announced investigations into potential investor claims, adding a possible reputational and legal overhang. Ionis Pharmaceuticals Investigation Notice

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals is a biotechnology company that discovers and develops RNA-targeted medicines, with a focus on antisense oligonucleotides. Its medicines are designed to act on RNA and change the production of proteins linked to disease. The company’s research and development programs span neurological, cardiovascular, metabolic and rare diseases. Ionis has developed medicines that it commercializes itself and products advanced or marketed with pharmaceutical partners. Its medicines and partnered products include treatments for conditions such as spinal muscular atrophy and transthyretin amyloidosis.